November, erasing the stock’s losses for the year amid a series of news flows. ・Tradipitant previously failed in ...

Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...

Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, ...

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the ...

Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing ...

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...

Vanda Pharmaceuticals (VNDA) announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not ...